355 related articles for article (PubMed ID: 30669)
1. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.
Sharon P; Ligumsky M; Rachmilewitz D; Zor U
Gastroenterology; 1978 Oct; 75(4):638-40. PubMed ID: 30669
[TBL] [Abstract][Full Text] [Related]
2. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine.
Ligumsky M; Karmeli F; Sharon P; Zor U; Cohen F; Rachmilewitz D
Gastroenterology; 1981 Sep; 81(3):444-9. PubMed ID: 6114012
[TBL] [Abstract][Full Text] [Related]
3. Flufenamic acid inhibition of PGE2 production by rectal mucosa in ulcerative colitis.
Rachmilewitz D; Ligumsky M; Sharon P; Karmeli F; Zor U
Gastroenterology; 1978 Nov; 75(5):929-30. PubMed ID: 29819
[No Abstract] [Full Text] [Related]
4. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.
Eliakim R; Karmeli F; Razin E; Rachmilewitz D
Gastroenterology; 1988 Nov; 95(5):1167-72. PubMed ID: 2901995
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of prostaglandin synthetase in human rectal mucosa.
Hawkey CJ; Lo Casto M
Gut; 1983 Mar; 24(3):213-7. PubMed ID: 6131017
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin catabolism and ulcerative colitis: effect of sulphasalazine, 5-aminosalicylic acid and other drugs.
Pacheco S; Hillier K; Smith CL
Braz J Med Biol Res; 1990; 23(12):1323-34. PubMed ID: 1983789
[TBL] [Abstract][Full Text] [Related]
7. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid.
Peskar BM; Dreyling KW; Peskar BA; May B; Goebell H
Agents Actions; 1986 Jun; 18(3-4):381-3. PubMed ID: 2875632
[TBL] [Abstract][Full Text] [Related]
8. Ulcerative colitis: effect of sulphasalazine, its metabolites and indomethacin on the ability of human colonic mucosa to metabolize prostaglandins in vitro.
Hillier K; Mason PJ; Pacheco S; Smith CL
Br J Pharmacol; 1982 May; 76(1):157-61. PubMed ID: 6123357
[TBL] [Abstract][Full Text] [Related]
9. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory bowel disease: the in vitro effect of sulphasalazine and other agents on prostaglandin synthesis by human rectal mucosa.
Pacheco S; Hillier K; Smith CL
Braz J Med Biol Res; 1987; 20(2):221-30. PubMed ID: 2891390
[TBL] [Abstract][Full Text] [Related]
11. Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa.
Kolassa N; Becker R; Wiener H
Prostaglandins; 1985 Jan; 29(1):133-42. PubMed ID: 2858116
[TBL] [Abstract][Full Text] [Related]
12. Modulation of human colonic arachidonic acid metabolism by sulfasalazine.
Hawkey CJ; Boughton-Smith NK; Whittle BJ
Dig Dis Sci; 1985 Dec; 30(12):1161-5. PubMed ID: 2866075
[TBL] [Abstract][Full Text] [Related]
13. Effect of prednisolone on prostaglandin synthesis by rectal mucosa in ulcerative colitis: investigation by laminar flow bioassay and radioimmunoassay.
Hawkey CJ; Truelove SC
Gut; 1981 Mar; 22(3):190-3. PubMed ID: 7227851
[TBL] [Abstract][Full Text] [Related]
14. The effect of sulphasalazine withdrawal on rectal mucosal function and prostaglandin E2 release in inactive ulcerative colitis.
Rampton DS; Sladen GE
Scand J Gastroenterol; 1981; 16(1):157-9. PubMed ID: 6112788
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandins and ulcerative colitis, a warning.
Gerber JG
Gastroenterology; 1979 Mar; 76(3):658. PubMed ID: 34557
[No Abstract] [Full Text] [Related]
16. [Prostacyclin (PGI2) activity in the rectal mucosa of patients with ulcerative colitis (author's transl)].
Seyfried H; Sinzinger H; Silberbauer K
Wien Klin Wochenschr; 1980 Apr; 92(8):282-4. PubMed ID: 6773249
[TBL] [Abstract][Full Text] [Related]
17. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118
[TBL] [Abstract][Full Text] [Related]
18. Rectal mucosal prostaglandin E release and electrolyte transport in ulcerative colitis.
Rampton DS; Sladen GE; Bhakoo KK; Heinzelmann DI; Youlten LJ
Adv Prostaglandin Thromboxane Res; 1980; 8():1621-5. PubMed ID: 7377010
[No Abstract] [Full Text] [Related]
19. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls.
Lauritsen K; Hansen J; Bytzer P; Bukhave K; Rask-Madsen J
Gut; 1984 Nov; 25(11):1271-8. PubMed ID: 6149981
[TBL] [Abstract][Full Text] [Related]
20. Leukotrienes in Crohn's disease: effect of sulfasalazine and 5-aminosalicylic acid.
Dreyling KW; Hoppe U; Peskar BA; Schaarschmidt K; Peskar BM
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():339-43. PubMed ID: 2889333
[No Abstract] [Full Text] [Related]
[Next] [New Search]
